Skip to main content
Erschienen in: Breast Cancer Research 2/2004

01.04.2004 | Commentary

Microarrays bring new insights into understanding of breast cancer metastasis to bone

verfasst von: Danny R Welch

Erschienen in: Breast Cancer Research | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Using a microarray approach, Kang and colleagues identified several genes involved in the generation of breast cancer metastasis in bone and demonstrated their roles in bone colonization in vivo. Their findings and interpretations are reviewed in the context of recent array studies that compared gene expression in primary tumors and metastases. RNA expression array results have already demonstrated value in predicting whether metastases will develop in patients. They have also shown that expression patterns are similar in primary tumors and metastases. The latter data have invited re-examination of long-held notions related to mechanisms of metastasis. While the arrays show promise for improving diagnostic capability in breast cancers, ascribing mechanistic interpretations to correlative data should be done with extreme caution. Kang and colleagues' paper in Cancer Cell elegantly reinforces the concepts that efficiency of the metastatic process is dependent on the coordinated expression of multiple genes and that the expression of metastasis-associated genes is sometimes dependent on the microenvironment in which cells find themselves.
Literatur
1.
Zurück zum Zitat Kang YB, Siegel PM, Shu WP, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003, 3: 537-549.CrossRefPubMed Kang YB, Siegel PM, Shu WP, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003, 3: 537-549.CrossRefPubMed
2.
Zurück zum Zitat Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 1889, 1: 571-573.CrossRef Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 1889, 1: 571-573.CrossRef
3.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Aksien LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Aksien LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
4.
Zurück zum Zitat Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.PubMedCentralCrossRefPubMed Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Van't Veer LJ, Dai HY, van de Vijver MJ, He YDD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.CrossRef Van't Veer LJ, Dai HY, van de Vijver MJ, He YDD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.CrossRef
6.
Zurück zum Zitat Van de Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AMM, Voskkuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed Van de Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AMM, Voskkuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed
7.
Zurück zum Zitat Van't Veer LJ, DeJong D: The microarray way to tailored cancer treatment. Nat Med. 2002, 8: 13-14. 10.1038/nm0102-13.CrossRef Van't Veer LJ, DeJong D: The microarray way to tailored cancer treatment. Nat Med. 2002, 8: 13-14. 10.1038/nm0102-13.CrossRef
8.
Zurück zum Zitat Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003, 33: 49-54. 10.1038/ng1060.CrossRefPubMed Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003, 33: 49-54. 10.1038/ng1060.CrossRefPubMed
9.
Zurück zum Zitat Bernards R, Weinberg RA: Metastasis genes: a progression puzzle. Nature. 2002, 418: 823-10.1038/418823a.CrossRefPubMed Bernards R, Weinberg RA: Metastasis genes: a progression puzzle. Nature. 2002, 418: 823-10.1038/418823a.CrossRefPubMed
10.
Zurück zum Zitat Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988, 319: 1239-1245.CrossRefPubMed Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988, 319: 1239-1245.CrossRefPubMed
11.
Zurück zum Zitat Van't Veer LJ, Weigelt B: Road map to metastasis. Nat Med. 2003, 9: 999-1000. 10.1038/nm0803-999b.CrossRefPubMed Van't Veer LJ, Weigelt B: Road map to metastasis. Nat Med. 2003, 9: 999-1000. 10.1038/nm0803-999b.CrossRefPubMed
12.
Zurück zum Zitat Fidler IJ, Kripke ML: Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population [letter]. Nat Genet. 2003, 34: 23-10.1038/ng0503-23a.CrossRefPubMed Fidler IJ, Kripke ML: Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population [letter]. Nat Genet. 2003, 34: 23-10.1038/ng0503-23a.CrossRefPubMed
13.
Zurück zum Zitat Hynes RO: Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants–or both?. Cell. 2003, 113: 821-823.CrossRefPubMed Hynes RO: Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants–or both?. Cell. 2003, 113: 821-823.CrossRefPubMed
14.
Zurück zum Zitat Luria SE, Delbrück M: Mutations of bacteria from virus sensitivity to virus resistance. Genetics. 1943, 28: 491-511.PubMedCentralPubMed Luria SE, Delbrück M: Mutations of bacteria from virus sensitivity to virus resistance. Genetics. 1943, 28: 491-511.PubMedCentralPubMed
16.
Zurück zum Zitat Butler TP, Gullino PM: Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975, 35: 512-516.PubMed Butler TP, Gullino PM: Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975, 35: 512-516.PubMed
17.
Zurück zum Zitat Talmadge JE, Wolman SR, Fidler IJ: Evidence for the clonal origin of spontaneous metastases. Science. 1982, 217: 361-363.CrossRefPubMed Talmadge JE, Wolman SR, Fidler IJ: Evidence for the clonal origin of spontaneous metastases. Science. 1982, 217: 361-363.CrossRefPubMed
18.
Zurück zum Zitat Hunter K, Welch DR, Liu ET: Genetic background is an important determinant of metastatic potential. Nat Genet. 2003, 34: 23-24. 10.1038/ng0503-23b.CrossRefPubMed Hunter K, Welch DR, Liu ET: Genetic background is an important determinant of metastatic potential. Nat Genet. 2003, 34: 23-24. 10.1038/ng0503-23b.CrossRefPubMed
19.
Zurück zum Zitat Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW: Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer. 1998, 77: 640-644. 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8.CrossRefPubMed Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW: Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer. 1998, 77: 640-644. 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8.CrossRefPubMed
20.
Zurück zum Zitat Müller A, Homey B, Soto H, Ge NF, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410: 50-56. 10.1038/35065016.CrossRefPubMed Müller A, Homey B, Soto H, Ge NF, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410: 50-56. 10.1038/35065016.CrossRefPubMed
21.
Zurück zum Zitat Shevde LA, Welch DR: Metastasis suppressor pathways–an evolving paradigm. Cancer Lett. 2003, 198: 1-20. 10.1016/S0304-3835(03)00304-5.CrossRefPubMed Shevde LA, Welch DR: Metastasis suppressor pathways–an evolving paradigm. Cancer Lett. 2003, 198: 1-20. 10.1016/S0304-3835(03)00304-5.CrossRefPubMed
22.
Zurück zum Zitat Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003, 3: 55-63. 10.1038/nrc967.CrossRefPubMed Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003, 3: 55-63. 10.1038/nrc967.CrossRefPubMed
23.
Zurück zum Zitat Welch DR, Rinker-Schaeffer CW: What defines a useful marker of metastasis in human cancer?. J Natl Cancer Inst. 1999, 91: 1351-1353. 10.1093/jnci/91.16.1351.CrossRefPubMed Welch DR, Rinker-Schaeffer CW: What defines a useful marker of metastasis in human cancer?. J Natl Cancer Inst. 1999, 91: 1351-1353. 10.1093/jnci/91.16.1351.CrossRefPubMed
24.
Zurück zum Zitat Goldberg SF, Harms JF, Quon K, Welch DR: Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metastasis. 1999, 17: 601-607. 10.1023/A:1006718800891.CrossRefPubMed Goldberg SF, Harms JF, Quon K, Welch DR: Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metastasis. 1999, 17: 601-607. 10.1023/A:1006718800891.CrossRefPubMed
25.
Zurück zum Zitat Chekmareva MA, Kadkhodaian MM, Hollowell CMP, Kim H, Yoshida BA, Luu HH, Stadler WM, Rinker-Schaeffer CW: Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. Cancer Res. 1998, 58: 4963-4969.PubMed Chekmareva MA, Kadkhodaian MM, Hollowell CMP, Kim H, Yoshida BA, Luu HH, Stadler WM, Rinker-Schaeffer CW: Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. Cancer Res. 1998, 58: 4963-4969.PubMed
26.
Zurück zum Zitat Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW: Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 1999, 59: 5483-5487.PubMed Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW: Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 1999, 59: 5483-5487.PubMed
27.
Zurück zum Zitat Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, Wilson SM, Morris VL, Groom AC, Chambers AF: Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 2002, 62: 2162-2168.PubMed Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, Wilson SM, Morris VL, Groom AC, Chambers AF: Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 2002, 62: 2162-2168.PubMed
28.
Zurück zum Zitat MacDonald IC, Groom AC, Chambers AF: Cancer spread and micrometastasis development: quantitative approaches for in vivo models. BioEssays. 2002, 24: 885-893. 10.1002/bies.10156.CrossRefPubMed MacDonald IC, Groom AC, Chambers AF: Cancer spread and micrometastasis development: quantitative approaches for in vivo models. BioEssays. 2002, 24: 885-893. 10.1002/bies.10156.CrossRefPubMed
Metadaten
Titel
Microarrays bring new insights into understanding of breast cancer metastasis to bone
verfasst von
Danny R Welch
Publikationsdatum
01.04.2004
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 2/2004
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr736

Weitere Artikel der Ausgabe 2/2004

Breast Cancer Research 2/2004 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.